Collaboration – November 11, 2026
Orexo and SVF Vaccines have started a research collaboration to find out whether Orexo’s powder-based formulation technology, AmorphOX, can be used to develop stable powder formulations of mRNA vaccines encapsulated in lipid nanoparticles (LNPs).
Pharma Business – November 11, 2026
The EMA’s Committee for Orphan Medicinal Products (COMP) has recommended that Ascendis Pharma’s once-weekly TransCon CNP (navepegritide) keep its orphan designation for achondroplasia in children. Once adopted by the European Commission, this would give the drug 10 years of market exclusivity in the EU.
Clinical Trials – November 11, 2026
Boehringer Ingelheim has started Phase 2 development of BI 3034701, a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist partnered with Gubra, triggering a EUR 10 million milestone payment, Gubra said in its third-quarter trading statement. It is the second Gubra-partnered obesity program to reach Phase 2 this year, after AbbVie’s ABBV-295.
Collaboration – November 10, 2026
Mendus has been granted SEK 977,300 by Vinnova to establish manufacturing of memory NK cell therapies with its partner NorthX Biologics, alongside the ongoing large-scale production of its lead candidate vididencel.
Intellectual Property – November 10, 2026
The US Patent and Trademark Office has granted Medivir a patent covering fostrox in combination with lenvatinib for liver cancer, with protection now running until at least January 2044, almost three years longer than previously communicated.
Clinical Trials – November 10, 2026
Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, did not increase the risk of major cardiovascular events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial. With this result, the registrational SYNCHRONIZE program in obesity is complete.
Clinical Trials – November 11, 2026
Boehringer Ingelheim has started Phase 2 development of BI 3034701, a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist partnered with Gubra, triggering a EUR 10 million milestone payment, Gubra said in its third-quarter trading statement. It is the second Gubra-partnered obesity program to reach Phase 2 this year, after AbbVie’s ABBV-295.
Clinical Trials – November 10, 2026
Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, did not increase the risk of major cardiovascular events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial. With this result, the registrational SYNCHRONIZE program in obesity is complete.
Clinical Trials – November 9, 2026
Full results from Novo’s Phase 3 ZEUS trial confirm that the IL-6 inhibitor ziltivekimab did not reduce the risk of heart attack, stroke or cardiovascular death in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. The data were presented at the American Heart Association’s Scientific Sessions 2026 and published in the New England Journal of Medicine.
Clinical Trials – November 5, 2026
Finnish Herantis Pharma has extended the placebo-controlled period of its upcoming Phase II study of HER-096 in Parkinson’s disease. The company points to newly published evidence that smartphone-based motor assessments detect disease progression more sensitively than conventional clinical measures.
Clinical Trials – November 4, 2026
Uppsala-based Abera Bioscience has received approval from the Dutch Central Committee on Research Involving Human Subjects (CCMO) to start a Phase I trial of its nasal pneumococcal vaccine candidate Ab-01.12. The approval marks the company’s move from preclinical to clinical development.
Clinical Trials – November 3, 2026
Camurus has dosed the first patient in LUNAR-2, a randomized, double-blind, placebo-controlled Phase IIb study of CAM2056, its monthly semaglutide depot, in people with overweight or obesity.
PharmaRelations
Do you have a strong network in the Finnish Life Science industry and enjoy turning relationships into business opportunities?
PharmaRelations
PharmaRelations is looking for a Head of Regulatory Affairs Development to lead and further develop our Regulatory Affairs services in the drug development space.
PharmaRelations
PharmaRelations is now looking for a Head of Clinical Operations in Denmark who wants to continue to build and develop our business in Denmark and south of Sweden (Öresundsregionen).
Karl Storz Endoskop Sverige AB
KARL STORZ är ett tyskt medicintekniskt företag som specialiserar sig på tillverkning och försäljning av endoskopisk utrustning och kirurgiska instrument. Företaget grundades 1945 i Tuttlingen av Dr. Karl Storz och har en lång historia av innovation inom medicinsk teknik.
Micrel Medical Device
On behalf of Micrel Medical Devices, we are looking for an ambitious and commercially driven Area Sales Manager to develop and grow the Danish market in a newly established position.
PharmaRelations
Lead strategy, consulting and business growth across the Nordic Life Science market.
In a new job – November 10, 2026
Getinge has appointed Stacy Beske as President of Acute Care Therapies and a member of the executive management team. She will report to President and CEO Mattias Perjos and take up the role on December 1, 2026.
In a new job – November 9, 2026
Malin Parkler, who has led Pfizer’s Swedish organization for more than a decade, will take on a one-year assignment as Europe Cluster Lead, Global Hospital & Biosimilars, on December 1, 2026. Caglar Ceritoglu, North Europe Cluster President, will step in as Acting Country Lead in Sweden.
In a new job – November 5, 2026
Sarah Fredriksson, former CEO of Aqilion and founder of Genovis, took over as CEO of AAX Biotech on November 1, 2026. Co-founder Daniel X Johansson remains Chief Scientific Officer (CSO) and board member.
Careers article – October 20, 2026
Stamina, mentors, passion, and a life outside the lab. When Nordic Life Science profiled five leaders from across the region’s life science industry, from investors to a startup founder to two of its leading scientists, each shared advice for people starting out. Their answers had a lot in common.
Career choice – September 14, 2026
From Stanford’s sunlit engineering quad to SciLifeLab’s brisk knowledge hub in Stockholm, Emma Lundberg works across two distinct innovation cultures. She sees lessons for Sweden in Silicon Valley’s close links between academia, investors, and industry, but also strengths at home that should not be lost.
Careers article – August 14, 2026
Returning to work after a long, relaxing vacation can be challenging. Here are some tips to make the transition easier and less stressful.
Profiles in Business – October 18, 2026
Sesselja Ómarsdóttir has spent her career moving between academia and industry, from lichen chemistry in an Icelandic lab to leading Genis today. She talks about mentorship, curiosity, and what it means to keep one foot in each world.
Profiles in Business – October 12, 2026
Finnish Heidi Haikala has a foot in two life science worlds. As a cancer researcher she has established her own research group at the University of Helsinki and Tampere University, and she is also a co-founder of the startup company Solid IO.
Profiles in Business – October 4, 2026
Unbeknownst to her, Jessica Martinsson’s long and varied career in research and life sciences was preparing her for her newest and possibly most influential role.
Pharma Business – November 10, 2026
The European Commission has approved an expanded label for Oncopeptides’ Pepaxti (melflufen) in multiple myeloma. The drug can now be used in adults who have received at least two prior lines of therapy and whose disease is refractory to lenalidomide and the last line of therapy.
Pharma article – November 9, 2026
Each person with opioid dependence who starts or stays in treatment for a year is associated with an estimated GBP 140,876 in lower societal costs in the UK. That is the finding of a new study by Lund-based Camurus and the Swedish Institute for Health Economics (IHE).
Agreement – November 9, 2026
The company has entered into an exclusive licence and distribution agreement with Canadian pharmaceutical company Kye Pharmaceuticals for Zeqmelit, a rapidly dissolving dexamethasone oral film, in Canada.
Agreement – November 4, 2026
Finnish Nightingale Health has signed two proteomics service agreements worth USD 1 million each, one with Alzheimer’s Research UK and one with medical research organization LifeArc. Both cover analysis of UK Biobank samples for research into neurodegenerative diseases.
Business Award – October 30, 2026
Copenhagen-based Evaxion has won the 2026 International Prix Galien Award for best digital health solution for its AI-Immunology platform. It is the first time a Danish company has received the prestigious award.
MedTech Business – October 29, 2026
Glycorex Transplantation is broadening its strategy to develop standardized, universal blood products for civilian healthcare, emergency preparedness, and military medicine. The work will be carried out through its new subsidiary, Glycorex Universal Blood Products (UBP).
Biotech Business – November 3, 2026
Trondheim-based Vitroscope has raised USD 7 million, made up of a USD 5 million seed round co-led by Cerberus Ventures and YZR Capital and USD 2 million in non-dilutive funding from the Research Council of Norway.
Biotech Business – November 3, 2026
Rayca Precision, which operates in Helsinki and London, has partnered with Dutch TechBio company QurieGen to offer pharma and biotech R&D teams a joint workflow that connects the discovery of new drug targets with the design and testing of drug candidates.
Biotech Business – November 2, 2026
Swedish biotech BioInvent plans a rights issue of approximately SEK 430 million to fund development of its anti-TNFR2 antibody BI-1808 and its other priority programs. The company also proposes to cut up to 20 positions.
Funding – October 30, 2026
Dr. Di Yu, co-founder of Uppsala-based Elicera Therapeutics, has received a grant of SEK 4 million from the Swedish Research Council to study how CAR-T cells can be designed to survive longer in the body and penetrate solid tumors more easily.
Funding – October 27, 2026
Researchers at Karolinska Institutet have been granted a total of SEK 59 million from the Swedish research council Formas for two new research programs on how climate change affects human health.
Science Award – October 27, 2026
Forska!Sverige has established a new entrepreneurship award in memory of inventor and entrepreneur Leif Lundblad. The first recipient is Ulf Landegren, Professor of Molecular Medicine at Uppsala University, who has built several successful life science companies while helping other researchers do the same.
This site uses cookies
